Comparison of Esomeprazole Versus Vonoprazan in Gastroesophageal Reflux Disease

Comparison of Effectiveness in Patients of Gastroesophageal Reflux Disease Taking Esomeprazole Versus Vonoprazan.

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07563491

Enrollment

824

Registered

2026-05-04

Start date

2025-01-01

Completion date

2025-09-30

Last updated

2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastro Esophageal Reflux

Brief summary

Local literature is deprived of data comparing the effectiveness of esomeprazole and vonoprazan in patients with gastroesophageal reflux disease (GERD). This study was planned with the objective of comparing the effectiveness of esomeprazole versus vonoprazan in patients diagnosed with GERD.

Detailed description

Addressing the pressing need for an in-depth understanding and comparison of treatment options for the escalating prevalence of GERD, a condition significantly impacting patients' quality of life, is crucial. The study's results would not only provide local data, but also help doctors choose between esomeprazole and vonoprazan as the best treatment option. This would improve patient care and help doctors make better decisions, which would ultimately lead to better management of GERD and the overall health of patients.

Interventions

DRUGEsomeprazole

Patients received a once-daily dose of 20 mg of esomeprazole after the evening meal for 4 weeks.

DRUGVonoprazan

Patients received a once-daily dose of 20 mg of vonoprazan after the evening meal for 4 weeks.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Any gender * Aged 18 to 65 years * Presenting with GERD

Exclusion criteria

* Patients with hepatic, renal, respiratory, or cardiac disease accessed on history and medical records. * Any previous history of malignancy accessed from medical records. * Pregnancy and Lactation * Currently using histamine-2 receptor antagonists, antacids, gastrointestinal motility stimulants, and steroids. * History of drug allergy to proton pump Inhibitors (PPIs).

Design outcomes

Primary

Measure	Time frame	Description
Sufficient relief	4 weeks	The frequency of patients who achieved sufficient relief was noted.

Countries

Pakistan

Contacts

PRINCIPAL_INVESTIGATORFaraz Ahmad

Allama Iqbal teaching hospital Dera Ghazi Khan

STUDY_DIRECTORMujahid Iqbal, FCPS